13.4 C
New York
Tuesday, April 30, 2024
HomeMarkets
Markets

12 Biggest Mid-Day Gainers For Friday

By Insider Scoop
0
32
psw-placeholder
psw-placeholder

Courtesy of Benzinga.

  • Stone Energy Corporation (NYSE: SGY) shares surged 16.7 percent to $14.07. Stone Energy shares have dropped 88.55 percent over the past 52 weeks, while the S&P 500 index has gained 1.45 percent in the same period.
  • Aldeyra Therapeutics Inc (NASDAQ: ALDX) shares jumped 12.7 percent to $6.41. Stifel Nicolaus initiated coverage of Aldeyra Therapeutics with a Buy rating.
  • AEterna Zentaris Inc. (USA) (NASDAQ: AEZS) shares climbed 12.3 percent to $3.66 as the company reported that it has signed an exclusive license agreement with Cyntec, an affiliate of Orient EuroPharma Co, for Zoptrex.
  • Kinross Gold Corporation (USA) (NYSE: KGC) gained 6.8 percent to $5.22. Macquarie upgraded Kinross Gold from Underperform to Neutral.
  • Thor Industries, Inc. (NYSE: THO) shares gained 6.6 percent to $69.04 after the company disclosed the acquisition of Jayco, Corp. for about $576 million in cash.
  • Mesoblast limited (ADR) (NASDAQ: MESO) shares rose 5.6 percent to $4.21 after the company issued an update on heart failure trial and funding of clinical operations. Mesoblast projects to do interim analysis for Phase 3 endpoints in Q1 2017
  • Netflix, Inc. (NASDAQ: NFLX) gained 5.5 percent to $96.45. Canaccord Genuity initiated coverage on Netflix with a Buy rating and a $120.00 price target.
  • Harmony Gold Mining Co. (ADR) (NYSE: HMY) rose 5.3 percent to $3.80. Macquarie upgraded Harmony Gold Mining from Underperform to Neutral.
  • Pan American Silver Corp. (USA) (NASDAQ: PAAS) shares gained 4.4 percent to $17.17. Silver futures gained 4.6 percent to trade at $19.49 an ounce.
  • Randgold Resources Ltd. (ADR) (NASDAQ: GOLD) gained 4.3 percent to $116.78. Macquarie upgraded Randgold from Neutral to Outperform. Gold futures gained 1.4 percent to $1,338.90 an ounce.
  • Galectin Therapeutics Inc (NASDAQ: GALT) shares rose 3.4 percent to $1.52. Roth Capital assumed Galectin Therapeutics with a Buy rating.
  • Array Biopharma Inc (NASDAQ: ARRY) shares rose 3.1 percent to $3.67 after the company reported the submission of NDA for binimetinib to the FDA.

Posted-In: Mid-Day GainersNews Intraday Update Markets Movers

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments

Stay Connected

157,303FansLike
396,312FollowersFollow
2,290SubscribersSubscribe

Latest Articles

Load more

Note: The material presented in this commentary is provided for informational purposes only and is based upon information that is considered to be reliable. However, neither PSW Investments, LLC d/b/a PhilStockWorld (PSW) nor its affiliates warrant its completeness, accuracy or adequacy and it should not be relied upon as such. Neither PSW nor its affiliates are responsible for any errors or omissions or for results obtained from the use of this information. Past performance, including the tracking of virtual trades and portfolios for educational purposes, is not necessarily indicative of future results. Neither Phil, Optrader, or anyone related to PSW is a registered financial adviser and they may hold positions in the stocks mentioned, which may change at any time without notice. Do not buy or sell based on anything that is written here, the risk of loss in trading is great.

This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities or other financial instruments mentioned in this material are not suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only intended at the moment of their issue as conditions quickly change. The information contained herein does not constitute advice on the tax consequences of making any particular investment decision. This material does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation to you of any particular securities, financial instruments or strategies. Before investing, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.

Contact us: support@philstockworld.com

© Copyright - PSW, LLC.

2024
0
Would love your thoughts, please comment.x
()
x